Work

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9036

Authors: Leena Gandhi, Pasi A. Janne, Mateusz Opyrchal, Suresh S. Ramalingam, Igor I. Rybkin, Navid Hafez, Luis E. Raez, Dmitry Gabrilovich, Fang Wang, Peter Ordentlich, Susan Brouwer, Serap Sankoh, Emmett V. Schmidt, Michael L. Meyers, Matthew David Hellmann

Institutions: NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, Roswell Park Comprehensive Cancer Center, Emory University, Winship Cancer Institute, Henry Ford Health, Henry Ford Hospital, Yale Cancer Center, Florida International University, The Wistar Institute, Syndax Pharmaceuticals (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890578922

Cites:

Cited by: 21

Related to: 10